KR20030047970A - Composition of electrodes for transdermal glucose monitoring bio-sensor - Google Patents
Composition of electrodes for transdermal glucose monitoring bio-sensor Download PDFInfo
- Publication number
- KR20030047970A KR20030047970A KR1020030035005A KR20030035005A KR20030047970A KR 20030047970 A KR20030047970 A KR 20030047970A KR 1020030035005 A KR1020030035005 A KR 1020030035005A KR 20030035005 A KR20030035005 A KR 20030035005A KR 20030047970 A KR20030047970 A KR 20030047970A
- Authority
- KR
- South Korea
- Prior art keywords
- working electrode
- glucose
- electrode
- platinum
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 49
- 239000008103 glucose Substances 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 238000012544 monitoring process Methods 0.000 title description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000017 hydrogel Substances 0.000 claims abstract description 12
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 10
- 108010015776 Glucose oxidase Proteins 0.000 claims abstract description 9
- 239000004366 Glucose oxidase Substances 0.000 claims abstract description 9
- 229940116332 glucose oxidase Drugs 0.000 claims abstract description 9
- 235000019420 glucose oxidase Nutrition 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000006641 stabilisation Effects 0.000 claims description 9
- 238000011105 stabilization Methods 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 7
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 229920001798 poly[2-(acrylamido)-2-methyl-1-propanesulfonic acid] polymer Polymers 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 238000001223 reverse osmosis Methods 0.000 claims description 2
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 20
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 abstract description 13
- 238000005259 measurement Methods 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 3
- 239000010839 body fluid Substances 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 2
- 239000007772 electrode material Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000840 electrochemical analysis Methods 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
- C12Q1/006—Enzyme electrodes involving specific analytes or enzymes for glucose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
역이온삼투 현상을 이용하여 피부 조직을 통해 체액을 추출하여, 추출된 물질 내의 글루코스 농도를 안정화로 체내 글루코스 농도, 즉 혈당량을 유추할 수 있는 기술을 구현함에 있어, 글루코스 산화효소를 포함하는 글루코스 측정 장치의 하이드로겔 내에서 발생하는 최종 화학 생성물인 과산화수소를 직접 접촉하는 전극의 성능은 전체 기기의 성능을 좌우하는 중요한 요소이다. 이에 본 발명에서는 전극의 성분 물질을 백금(Pt)과 탄소(C)로 정하고, 이들 물질의 조성에 따른 성능 변화를 관찰하여 최적의 조성을 찾아 글루코스 측정용 전극 물질의 성능을 최대화하였다.Extracting body fluid through skin tissue using reverse ion osmosis, stabilizing glucose concentration in the extracted substance, and implementing a technique that can infer glucose concentration in the body, that is, blood glucose level, measurement of glucose including glucose oxidase The performance of the electrode in direct contact with hydrogen peroxide, the final chemical product generated in the hydrogel of the device, is an important factor in determining the performance of the entire device. Accordingly, in the present invention, the component materials of the electrode are set to platinum (Pt) and carbon (C), and the performance change according to the composition of these materials is observed to find an optimal composition to maximize the performance of the electrode material for glucose measurement.
Description
본 발명은 인체의 표피 근처에 존재하는 체액 중 일정 생화학 성분을 추출하여, 그 농도를 모니터하는데 사용되는 경피추출형 바이오센서의 구성요소 중 전기신호를 발생하는 작업전극(working electrode,WE), 상대전극(counter electrode,CE), 기준전극(reference electrode,RE)에 관한 것이다. 본 발명의 중요한 적용으로는 비침입식 경피 혈당 모니터 시스템이 있다.The present invention extracts a certain biochemical component from the body fluids present near the epidermis of the human body, and works electrode (WE), relative to generate an electrical signal among the components of the transdermal extraction biosensor used to monitor its concentration. The present invention relates to a counter electrode (CE) and a reference electrode (RE). An important application of the present invention is a non-invasive transdermal blood glucose monitoring system.
당뇨병은 인슐린 분비 부족이나 인슐린에 대한 세포반응성 저하로 인해 음식물이 소화되어 얻어지는 글루코스(포도당)가 인체 내 혈액에 축적되며 동맥경화증 고혈압 뇌혈관 경색증과 같은 심혈관계 질환, 당뇨병성 신증과 같은 신장 질환, 당뇨병성 망막증이나 백내장과 같은 안질환, 농피증이나 괴저와 같은 피부질환, 치주농루와 같은 구강질환 등의 합병증을 유발하는 난치성의 질병이다. 사회 경제적인 발전이 이루어지면서 과식, 운동부족, 스트레스 증가 등으로 인하여 당뇨병 인구는 현저히 증가하는 추세이며, 선진화되어있는 국가의 경우 전체인구 대비 5∼10%가 당뇨병 환자로 추정되고 있으며, 이들 중 50%가량은 본인이 당뇨병 환자임을 인식하지 못하고 있는 상황이다. 당뇨환자는 기본적으로 공복시와 (허용 최대치 140 mg/dL), 식후 2시간 (허용최대치 200 mg/dL)혈당량을 주기적으로 모니터함으로써 자신의 혈당량을 관리하는 것이 권장되고 있다. 이 외에도 전신 상태, 섭취하는 음식물의 종류와 양, 나이, 합병증의 유무, 스트레스, 기타 동반된 질환 등 많은 여건들에 의하여 하루 중에도 혈당의 변동이 심하므로, 당뇨환자의 자가혈당 검사 및 관리는 환자의 건강 유지 및 합병증 예방에 매우 중요한 요소라고 할 수 있다.Diabetes can cause glucose (glucose), which is obtained by digesting foods due to insufficient insulin secretion or decreased cellular reactivity to insulin, to accumulate in the blood, cardiovascular diseases such as arteriosclerosis, hypertension, cerebrovascular infarction, kidney diseases such as diabetic nephropathy, It is a refractory disease that causes complications such as diabetic retinopathy, eye diseases such as cataracts, skin diseases such as pyoderma and necrosis, and oral diseases such as periodontal pylori. As socio-economic development has progressed, the diabetic population has increased significantly due to overeating, lack of exercise, and increased stress. In advanced countries, 5-10% of the total population is estimated to be diabetic. About% do not realize that they are diabetic. Diabetes patients are recommended to manage their blood glucose levels by periodically monitoring fasting (maximum tolerance 140 mg / dL) and 2 hours postprandial (maximum tolerance 200 mg / dL) blood glucose levels. In addition, blood sugar fluctuates during the day due to many conditions such as general condition, type and quantity of foods eaten, age, presence of complications, stress, and other accompanying diseases. Is a very important factor in maintaining health and preventing complications.
종래의 혈액내 글루코스, 즉 혈당의 모니터 방법은 주로 채혈식에 의존해 왔다. 즉 손가락 끝이나 기타 신체 특정부위에서 채혈침을 사용하여 혈액을 채취하는 방식으로 단발성의 검사만 가능한 단점이 있다. 또한 채혈식 혈당 모니터 시스템은 채혈시의 고통이나 불쾌감으로 인하여 짧은 주기로 혈당을 측정할 수 없는 불편이 있다. 이러한 불편을 제거하고, 연속적인 혈당 측정을 시도하기 위하여 다양한 방법의 연속측정형 혈당측정 시스템이 개발 중에 있다. 피하조직에 삽입하는 미세바늘형 혈당센서(미국의 MiniMed사)와 역이온 삼투요법을 사용하는 피부패취형(Cygnus사)의 2가지 제품이 사용되고 있으나 개선의 여지가 남아있고 그 사용이 널리 확산되고 있지 못한 상황이다. 이밖에도 압축가스, LASER, MEMS 기술로 제작한 미세바늘 등을 이용하여 피부의 최상층(stratum corneum)에 미세 구멍을 내고 이를 통하여 세포간질액(Interstitial Fluid)을 연속적으로 추출하는 방식의 연구개발이 진행중에 있다.Conventional methods of monitoring glucose in blood, ie blood glucose, have relied primarily on blood sampling. In other words, only a single test can be performed by using a needle to collect blood from a fingertip or other part of the body. In addition, the blood glucose monitoring system is inconvenient to measure blood glucose at short intervals due to pain or discomfort during blood collection. In order to eliminate this inconvenience and to attempt continuous blood glucose measurement, various methods of continuous measurement blood glucose measurement system are under development. There are two products, microneedle type blood glucose sensor (MiniMed, USA) and skin patch type (Cygnus company) using reverse ion osmosis, which are inserted into the subcutaneous tissue. There is no situation. In addition, the research and development of the method of extracting interstitial fluid continuously by making a micro hole in the stratum corneum using the microneedle produced using compressed gas, LASER, MEMS technology, etc. have.
따라서, 간편한 비침습형 자가 혈당 측정 시스템의 발명 및 적용이 본 기술분야에서 요구되고 있으며, 특히 그 핵심 요소라고 할 수 있는 분석 전극의 발명이 요구되는 정도는 매우 크다고 할 수 있다.Therefore, the invention and application of a simple non-invasive type of self blood glucose measurement system is required in the art, and the extent to which the invention of the analytical electrode, which can be said to be a key element thereof, is very large.
피부조직에 미량의 직류 전류를 가하여 음극쪽 성분을 분석하면 Na+, K+등의 양이온들과 중성의 글루코스 분자 성분이 추출되는 것은 잘 알려진 사실이다. 이러한 작용을 역이온삼투라 하며, 추출된 이들 글루코스 분자 성분은 혈액내의 글루코스 농도의 변화에 대해 상관 관계를 가지고 변화한다. 따라서 추출된 글루코스 농도를 측정하여 신뢰성 있는 혈당량을 추산하는 것이 가능하다.It is well known that the cathodic components such as Na + and K + and neutral glucose molecules are extracted by applying a small amount of direct current to skin tissue. This action is called reverse ion osmosis, and these extracted glucose molecule components change in correlation with changes in glucose concentration in the blood. Therefore, it is possible to estimate reliable blood glucose levels by measuring the extracted glucose concentration.
전극에 전류를 인가하여 글루코스와 같은 생화학물질을 추출하고자 할 때, 전극과 피부사이에는 글루코스 산화효소(Glucose Oxidase)와 같이 최종생성물이 과산화수소인 효소가 내부에 고정되어 있는 하이드로겔이 위치한다. 하이드로겔은 폴리에틸렌옥사이드, 폴리아크릴산, 폴리비닐알코올, 폴리아크릴아미도메틸프로판술폰산 등의 고분자 또는 이들의 공중합체로 이루어져 있다. 이들 고분자 하이드로겔은 공기에 과다히 노출되어 있지 않은 경우, 수 시간(약 12∼24시간) 함수율을 유지하여 내부환경을 일정히 유지할 수 있다. 이 하이드로겔 내에 중성의 생리학적 완충용액(Phosphate Buffer Saline)이 존재할 경우, 약간 양 생성된 산이나 반응물의 농도에 관계없이 글루코스 산화효소의 활성을 유지할 수 있다. 따라서 수회(약 70회/1일 이상)에 걸쳐 유효한 추산 혈당량을 계측할 수 있다.When extracting a biochemical such as glucose by applying a current to the electrode, between the electrode and the skin is a hydrogel in which the final product is an enzyme, such as glucose oxidase (hydrogen peroxide) is fixed inside. The hydrogel consists of a polymer such as polyethylene oxide, polyacrylic acid, polyvinyl alcohol, polyacrylamidomethylpropanesulfonic acid or a copolymer thereof. When the polymer hydrogel is not excessively exposed to air, the polymer hydrogel can maintain a water content for several hours (about 12 to 24 hours) and maintain a constant internal environment. In the presence of a neutral physiological buffer (Phosphate Buffer Saline) in the hydrogel, it is possible to maintain the activity of glucose oxidase irrespective of the concentration of slightly generated acid or reactant. Therefore, effective estimated blood glucose can be measured several times (about 70 times / day or more).
전기삼투압방식으로 피부를 통하여 체외로 추출되어 하이드로겔 내로 이동된 성분들 중 글루코스를 선택적 반응성이 있는 산화효소(Glucose oxidase)를 이용하여 아래의 반응식과 같이 과산화수소(H2O2)로 만들어 (1), 전기화학적인 방법으로 분석하면 (2), 체내의 글루코스를 추산할 수 있다.Among the components extracted out of the body through the electroosmotic pressure and transferred to the hydrogel, glucose was made into hydrogen peroxide (H 2 O 2 ) using the reactive oxidase (Glucose oxidase) as shown below. ), Electrochemical analysis (2) can estimate glucose in the body.
Glucose + O2+ GOD → H2O2+ Gluconic Acid (1)Glucose + O 2 + GOD → H 2 O 2 + Gluconic Acid (1)
H2O2→ 2e- + O2+ 2H+(2)H 2 O 2 → 2e- + O 2 + 2H + (2)
이 방법을 적용하였을때, 생체로부터 추출된 글루코스를 분석할 수 있는 최소양은 수십 내지 수백분의 1 nmole 까지도 가능하다. 이때 감도, 분해능, 최소검출한도, 신호 대 잡음비(S/N) 등의 시스템 성능을 결정하는 요소에는 여러 가지가 있으나 그 중에서도, 생성된 과산화수소를 분해하여 전자를 생성하는 전극의 화학적 조성의 증요성은 매우 크다. (2)의 반응이 완결되기 위해서 작업전극, 기준전극, 상대전극 으로 구성된 포함하는 3상전극계를 이용한다. 이 3 종류의 전극들 중 (2) 반응이 직접 발생하는 위치는 작업전극의 표면이다. 작업전극으로는 백금 전극이 사용될 수 있으나, 백금전극을 단독으로 사용하는 것 보다 탄소를 첨가하는 것이 물리, 화학적인 잇점을 가져올 수 있다.When this method is applied, the minimum amount to analyze glucose extracted from the living body can be from tens to hundreds of nanometers. At this time, there are many factors that determine system performance such as sensitivity, resolution, minimum detection limit, and signal-to-noise ratio (S / N), but among them, the chemical composition of the electrode that decomposes the generated hydrogen peroxide to generate electrons Is very large. In order to complete the reaction of (2), a three-phase electrode system including a working electrode, a reference electrode, and a counter electrode is used. Of these three types of electrodes, the position where reaction (2) occurs directly is the surface of the working electrode. A platinum electrode may be used as the working electrode, but adding carbon may bring physical and chemical advantages over using the platinum electrode alone.
본 발명에서는 여러 가지의 백금 대 탄소 조성비를 가지는 작업전극을 스크린법으로 인쇄 제작하여 각각의 성능을 확인하여 글루코스 정량분석을 위한 최적의 조성을 얻는 것을 목적으로한다. 즉 피부를 통해 체액 에서 역이온삼투압으로 추출된 글루코스 양을 측정하는 바이오 센서 시스템에, 위에서 얻어진 최적의 조성을 갖는 작업전극을 적용하고자 한다.In the present invention, a working electrode having various platinum-to-carbon composition ratios is printed and manufactured by a screen method, and an object thereof is to obtain an optimum composition for quantitative analysis of glucose by confirming each performance. In other words, it is intended to apply the working electrode having the optimum composition obtained in the biosensor system for measuring the amount of glucose extracted by the reverse osmosis pressure from the body fluid through the skin.
도 1은 역이온삼투압 경피 추출형 글루코스 모니터에 장착되는 전극 시스템으로1 is an electrode system mounted on a reverse ion osmotic transdermal extraction glucose monitor
A는 추출전극A is the extraction electrode
B는 작업전극B is the working electrode
C는 상대전극C is the counter electrode
D는 기준전극이다.D is a reference electrode.
도 2는 작업전극의 조성에 따른 측정전하량 함수 곡선이다.2 is a measurement charge function curve according to the composition of the working electrode.
전극은 도 1에 나타나 있는 형태와 같으며, A는 추출전극,B는 작업전극, C는 기준전극, 그리고 D는 상대전극이다. A와 D는 은/염화은(Ag/AgCl) 혼합물이 유기용매에 분산되어 있는 잉크를 스크린 프린트 방법으로 인쇄한 것이며, 그 두께는 100μm 정도이며, B와 C는 적절한 비율로 혼합된 백금/탄소 혼합물이 유기 용매에 분산되어 있는 잉크를 스크린 인쇄법으로 그 두께가 100μm 정도가 되도록 프린트한 전극이다. 이들 전극은 유전체인 세라믹이나 폴리머 물질의 기판위에 인쇄되어, 용매를 모두 휘발시킬 수 있는 온도에서 열처리하여 제작한다.The electrode is as shown in Figure 1, where A is the extraction electrode, B is the working electrode, C is the reference electrode, and D is the counter electrode. A and D are screen prints of ink in which a silver / silver chloride (Ag / AgCl) mixture is dispersed in an organic solvent. The thickness is about 100 μm, and B and C are platinum / carbon mixtures mixed in an appropriate ratio. It is an electrode which printed the ink disperse | distributed to this organic solvent so that the thickness might be about 100 micrometers by the screen printing method. These electrodes are printed on a substrate made of a ceramic or polymer material, which is a dielectric material, and manufactured by heat treatment at a temperature at which all the solvents can be volatilized.
백금과 탄소의 비율은 다음 표1과 같이 정하여 C와 D전극을 제작하였다.The ratio of platinum and carbon was determined as shown in Table 1 below to produce C and D electrodes.
이와같이 제작되는 작업전극이 글루코스 분석 바이오센서용 전극으로 사용되기 위해서는 전기화학적으로 제한된 특성이 요구된다.The working electrode manufactured as described above requires electrochemically limited properties to be used as an electrode for glucose analysis biosensors.
우선, 통상적인 3상전극계 일정전위 조건하에서, 하이드로겔이나 PBS 용액과 같은 매질이 전극위에 있을 때, 초기 구동시 포화되어 안정화되는 산화 전류값이 작을수록 바람직하다. 이는 피부 조직을 통해 추출된 글루코스 분자는 저농도로 검출되는 전기 신호가 작기 때문에 전류값을 바탕신호에서 효율적으로 구분하기 위해서는 안정화 전류값은 작을수록 바람직하다.First, under a conventional three-phase electrode system constant potential condition, when a medium such as a hydrogel or PBS solution is on the electrode, the smaller the oxidation current value that is saturated and stabilized during initial operation is preferable. This is because the glucose molecules extracted through the skin tissue have a low electric signal detected at low concentration, so that the stabilization current value is smaller in order to efficiently distinguish the current value from the background signal.
또한, 같은 농도의 글루코스 또는 과산화수소 양에 대해 상대적으로 높은 전류 신호를 발생시킬수록 좋은 전극이라고 할 수 있다. 이는 위에서 언급한 안정화값의 영향과 더불어 노이즈로부터 글루코스에 의한 전류 신호를 구분하는 것이 중요하기 때문이다.In addition, it is a good electrode to generate a relatively high current signal for the same concentration of glucose or hydrogen peroxide amount. This is because in addition to the influence of the stabilization values mentioned above, it is important to distinguish the current signal due to glucose from the noise.
마지막으로 같은 농도의 글루코스 또는 과산화수소 양에 대하여 작은 값의 노이즈를 가져야 한다. 통상 위와 같은 또는 유사한 전극 구조와 하이드로겔을 이용하여 경피 추출 글루코스에 의한 신호값은 대개 수 내지 수백 nA에 불과하므로, 수nA 크기의 노이즈도 결과 분석에 심각한 영향을 미칠 수 있다. 따라서, 노이즈의크기 또는 신호 대 잡음비(SNR)가 클수록 좋은 전극이라고 할 수 있다. 신호 대 잡음비는 다음 (3)식과 같다.Finally, there should be a small amount of noise for the same concentration of glucose or hydrogen peroxide. Typically, the signal value of transdermal extracted glucose using the same or similar electrode structure and hydrogel is usually only a few to several hundred nA, so a few nA noise may seriously affect the result analysis. Therefore, the greater the magnitude of noise or the signal-to-noise ratio (SNR), the better the electrode. The signal-to-noise ratio is given by the following equation (3).
SNR = 10 X log10(S/N) (3)SNR = 10 X log 10 (S / N) (3)
여기서 S는 신호의 크기, N은 노이즈의 크기이다.Where S is the magnitude of the signal and N is the magnitude of noise.
〈실시예1〉<Example 1>
글루코스용 바이오센서에서 전극 조성비에 따른 글루코스 산화전류 성능 평가 도 1과 같은 구조를 갖는 전극위에 동일한 두께의 동일 배치 하이드로겔을 이용하여 평가 장치를 구성하였다. 전기화학적 반응을 유도하고, 위의 반응을 통하여 발생한 전자의 흐름, 즉 전류를 측정하기 위하여 일정전위공급기(Potentiostat)를 사용하였다. 즉, 100μM의 글루코스가 (1), (2)의 반응을 통하여 GOD(Glucose Oxidase)와 반응하여 발생하는 과산화수소에 의한 전류변화를 통하여 글루코스 농도를 측정하였다.Evaluation of glucose oxidation current performance according to electrode composition ratio in the biosensor for glucose The evaluation device was configured by using the same batch hydrogel having the same thickness on the electrode having the structure as shown in FIG. 1. A potentiostat was used to induce an electrochemical reaction and to measure the flow of electrons, ie, the current generated through the above reaction. That is, the glucose concentration was measured by the current change by hydrogen peroxide generated by the reaction of 100 μM glucose with Glucose Oxidase (GOD) through the reaction of (1) and (2).
이때 안정화 전류값은 충분한 시간이 지난 후 안정된 후에 얻었으며, 그 값은 아래 표2 와 같다.At this time, the stabilization current value was obtained after stabilization after sufficient time, and the value is shown in Table 2 below.
음의 안정화전류가 충분히 안정된 후에 100μM 글루코스 용액 일정량을 하이드로겔 위에 도포하였다. 이후에 하강한 후 다시 안정화값에 도달하였을 때, 안정화값 아래 곡선을 적분하여, 글루코스에 의한 전하량 생성량을 측정하였다. 이 전하생성량은 같은 전극에 대해서는 주입한 글루코스의 농도와 직선적인 함수관계가 있다.After the negative stabilization current was sufficiently stable, a certain amount of 100 μM glucose solution was applied onto the hydrogel. Then, when descending after reaching the stabilization value, the curve under the stabilization value was integrated to measure the amount of charge generated by glucose. This charge generation amount has a linear functional relationship with the concentration of glucose injected into the same electrode.
그 결과는 도 2에 나타내었다.The results are shown in FIG.
전류신호가 거의 안정화값에 도달하였을 때 모든 전극에서 노이즈 폭은 최대에 달하였고, 그 값은 아래 표3와 같다.When the current signal nearly reached the stabilization value, the noise width reached the maximum at all electrodes, and the values are shown in Table 3 below.
신호 대 잡음 비는 백금이 탄소에 비해 50%, 70%일때 가장 좋았으며 백금의 함량이 많아 질수록 증가하였다. 노이즈 폭과 신호 대 잡음 비를 고려할 때에 백금이 50% 내지 70% 의 함량일 때에 최적의 성능임을 알 수 있다.The signal-to-noise ratio was the best when platinum was 50% and 70% compared to carbon, and increased as the platinum content increased. Considering the noise width and the signal-to-noise ratio, it can be seen that the optimum performance is achieved when the platinum content is 50% to 70%.
본 발명의 전극을 3상전극계 글루코스 추출용 바이오센서에 적용시킬 경우 최적의 생체 혈당 농도 분석을 수행할 수 있다.When the electrode of the present invention is applied to a three-phase electrode-based glucose extraction biosensor, optimal blood glucose concentration analysis can be performed.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030035005A KR100541266B1 (en) | 2003-05-30 | 2003-05-30 | Composition of electrode for transdermal glucose measurement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030035005A KR100541266B1 (en) | 2003-05-30 | 2003-05-30 | Composition of electrode for transdermal glucose measurement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030047970A true KR20030047970A (en) | 2003-06-18 |
| KR100541266B1 KR100541266B1 (en) | 2006-01-10 |
Family
ID=29579907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020030035005A Expired - Lifetime KR100541266B1 (en) | 2003-05-30 | 2003-05-30 | Composition of electrode for transdermal glucose measurement |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100541266B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040075301A (en) * | 2004-07-27 | 2004-08-27 | (주) 테크포엠 | Storing Method of Hydrogels for Biosensor or Drug Delivery System |
| KR100868566B1 (en) * | 2007-03-29 | 2008-11-13 | 케이엠에이치 주식회사 | Glucose concentration measuring device and method for measuring glucose concentration using the same |
| WO2017057792A1 (en) * | 2015-10-02 | 2017-04-06 | 주식회사 엔게인 | Polyhydroxyethylmethacrylate-based hydrogel, method for producing same, and glucose sensor comprising same |
| US10241022B2 (en) | 2017-03-30 | 2019-03-26 | Intel Corporation | Characterizing a fluid sample based on response of a non-planar structure |
| CN114965630A (en) * | 2022-06-06 | 2022-08-30 | 晨光生物科技集团股份有限公司 | Silk-screen printing electrode for detecting antioxidant activity and preparation and detection methods thereof |
-
2003
- 2003-05-30 KR KR1020030035005A patent/KR100541266B1/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040075301A (en) * | 2004-07-27 | 2004-08-27 | (주) 테크포엠 | Storing Method of Hydrogels for Biosensor or Drug Delivery System |
| KR100868566B1 (en) * | 2007-03-29 | 2008-11-13 | 케이엠에이치 주식회사 | Glucose concentration measuring device and method for measuring glucose concentration using the same |
| WO2017057792A1 (en) * | 2015-10-02 | 2017-04-06 | 주식회사 엔게인 | Polyhydroxyethylmethacrylate-based hydrogel, method for producing same, and glucose sensor comprising same |
| US10241022B2 (en) | 2017-03-30 | 2019-03-26 | Intel Corporation | Characterizing a fluid sample based on response of a non-planar structure |
| CN114965630A (en) * | 2022-06-06 | 2022-08-30 | 晨光生物科技集团股份有限公司 | Silk-screen printing electrode for detecting antioxidant activity and preparation and detection methods thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100541266B1 (en) | 2006-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9968284B2 (en) | Anti-interferent barrier layers for non-invasive transdermal sampling and analysis device | |
| Ribet et al. | Ultra-miniaturization of a planar amperometric sensor targeting continuous intradermal glucose monitoring | |
| RU2745479C1 (en) | Method and the electronics unit for determining biosensor properties under in vivo conditions | |
| US5954685A (en) | Electrochemical sensor with dual purpose electrode | |
| CA3210742A1 (en) | One-touch fingertip sweat sensor and personalized data processing for reliable prediction of blood biomarker concentrations | |
| Tierney et al. | Electroanalysis of glucose in transcutaneously extracted samples | |
| CZ20022020A3 (en) | Apparatus and method for percutaneous withdrawal of a biological liquid and analyte measuring | |
| US20190231263A1 (en) | Micro sensor | |
| HK1049951B (en) | Biological fluid sampling and analyte measurement device | |
| WO2005023111A1 (en) | Glucose sensor and glucose level measuring apparatus | |
| WO2011084607A1 (en) | Transdermal systems, devices, and methods for biological analysis | |
| Zhan et al. | A 3D-printed microneedle extraction system integrated with patterned electrodes for minimally invasive transdermal detection | |
| Liu et al. | Development of an amperometric biosensor on a toothbrush for glucose | |
| KR100541266B1 (en) | Composition of electrode for transdermal glucose measurement | |
| JP5021678B2 (en) | Electrochemical sensor system using substrate having at least one electrode and method of forming the same | |
| JP6538554B2 (en) | Cumulative measurement of analytes | |
| WO2016038529A1 (en) | Device and method for non-enzymatic and electrochemical detection of glucose bioanalyte | |
| EP3928697A1 (en) | Analyte sensor and a method for producing an analyte sensor | |
| KR20030047971A (en) | Transdermal Glucose biosensor | |
| WO2005055821A1 (en) | Reduction of settling time for an electrochemical sensor | |
| US20250228480A1 (en) | Biosensors and Methods for Determining Analyte Concentration in the Kinetic Potential Region of Redox Mediators with Single-Point Calibration | |
| US12216074B2 (en) | Biosensors and methods for determining analyte concentration in the kinetic potential region of redox mediators | |
| US12507923B2 (en) | Analyte sensor and a method for producing an analyte sensor | |
| US12507924B2 (en) | Analyte sensor and a method for producing an analyte sensor | |
| US20250241583A1 (en) | Touch-based biomarker monitoring system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20030530 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050317 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20051021 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20051229 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20051230 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20090629 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20091130 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20101103 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20111206 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20121203 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20121203 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20131224 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20131224 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20141229 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20141229 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20151228 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20151228 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20161228 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20161228 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20171219 Start annual number: 13 End annual number: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20181226 Start annual number: 14 End annual number: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20201221 Start annual number: 16 End annual number: 16 |
|
| PR1001 | Payment of annual fee |
Payment date: 20211216 Start annual number: 17 End annual number: 17 |
|
| PR1001 | Payment of annual fee |
Payment date: 20221219 Start annual number: 18 End annual number: 18 |
|
| PC1801 | Expiration of term |
Termination date: 20231129 Termination category: Expiration of duration |